OpenAI’s GPT-Rosalind signals the next phase: models built for one domain

The frontier isn’t just getting bigger, it’s getting more specialized. The introduction of GPT-Rosalind from OpenAI signals the arrival of domain-specific models. The first of these models will be for the life sciences.

Driving the news: Rosalind is a model developed exclusively for life science research. OpenAI has released the academic plan to provide eligible labs with sponsored access to this model (https://openai.com/index/introducing-the-rosalind-academic-plan).

The details:

• Labs in the eligible category can get up to 30 Business Standard seats free for up to 12 months, subject to trusted-access approval.
• GPT-Rosalind incorporates frontier reasoning and provides a “Rosalind workbench” to assist users with tools in the areas of medicinal chemistry and genomics as well as wet-lab assistance.

Why it matters: This is a different approach from a model that covers a broad range of domains. A model specific to a domain, like a domain-specific tool, may produce better results than a model constructed with general domain knowledge. We can expect other vertical domain models in finance, medicine and law, for example.

The AEO angle: As models become more specialized, the data sources they rely on become more specialized too. GPT-Rosalind will obviously rely more on PubMed, the FDA and primary research than a general model. That is exactly the shift we’ve already seen with ChatGPT, as Ahrefs data shows. More specialized models lean on more specialized sources, and will reward specialized authority more sharply.

The bottom line: “Which model” is becoming “which model, for what.” Generic content gets you into fewer and fewer of them.